frondanol

Frondanol is a **nutraceutical marine lipid extract** derived from the edible Atlantic sea cucumber *Cucumaria frondosa*, described in the literature as a US-patented extract with anti-inflammatory and chemopreventive activity. It has been developed and marketed as an oral capsule supplement rather than as a conventional pharmaceutical small molecule. Preclinical studies and the published clinical-trial protocol indicate that its proposed mechanism involves inhibition of **5-lipoxygenase** and **12-lipoxygenase** pathways, with downstream suppression of inflammatory eicosanoids such as **5-HETE**, **12-HETE**, and **LTB4** and reduction of pro-inflammatory cytokine signaling in colitis models. In public sources, Frondanol has been investigated clinically as an adjunctive oral treatment for mild to moderate inflammatory bowel disease, including ulcerative colitis and Crohn colitis, in a randomized placebo-controlled study using 1000 mg capsules twice daily.

Brand names

Frondanol

Other names

FrondanolFrondanolTM